TriangleNCT00095563 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From the date of study enrolment to death or last contact, assessed up to 5 years
What was measured
Survival estimates will be computed using the Kaplan-Meier method.
Analysis population: 20 participants with ACC, 19 participants with non-ACC.
Groups in this outcome
Treatment (Lapatinib Ditosylate)
Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. lapatinib ditosylate: Given orally laboratory biomarker analysis: Correlative studies
| Group | Source count |
|---|---|
| Treatment (Lapatinib Ditosylate) | 39 |
Reported measurements
ACC
| Group | Source count |
|---|---|
| Treatment (Lapatinib Ditosylate) | 20 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Lapatinib Ditosylate) | NA | Not reported | NA | NA | Not reached |
Non-ACC
| Group | Source count |
|---|---|
| Treatment (Lapatinib Ditosylate) | 19 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Lapatinib Ditosylate) | 16.5 | Not reported | 9.1 | 30.9 | Not reported |
Complete source fields
- classes
- categories
- measurements
- comment
- Not reached
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 20
- units
- Participants
- title
- ACC
- categories
- measurements
- group Id
- OG000
- lower Limit
- 9.1
- upper Limit
- 30.9
- value
- 16.5
- denoms
- counts
- group Id
- OG000
- value
- 19
- units
- Participants
- title
- Non-ACC
- denoms
- counts
- group Id
- OG000
- value
- 39
- units
- Participants
- description
- Survival estimates will be computed using the Kaplan-Meier method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. lapatinib ditosylate: Given orally laboratory biomarker analysis: Correlative studies
- id
- OG000
- title
- Treatment (Lapatinib Ditosylate)
- param Type
- MEDIAN
- population Description
- 20 participants with ACC, 19 participants with non-ACC.
- reporting Status
- POSTED
- time Frame
- From the date of study enrolment to death or last contact, assessed up to 5 years
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice